Protalix BioTherapeutics reports Q3 2026 financial results and business updates
Protalix BioTherapeutics recorded Q3 revenue of $75.6M and raised Q3 2026 guidance. The company also confirmed that its Phase 2 study for PRX-115 is on track, with results expected in late 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed